<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181030041507N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-12-31</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Prophylactic Effect of StrataXRT Gel on Radiation  Therapy Induced Dermatitis</public_title>
      <acronym></acronym>
      <scientific_title>The Investigation of Prophylactic Effect of StrataXRT Gel on Radiation  Therapy Induced Dermatitis in Breast Cancer Patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35019</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Among patients referring to the radiation oncology department of Namazi hospital in Shiraz, who have breast cancer and undergo radical mastectomy and candidate for radiotherapy, will be randomly underwent radiation therapy, and 100 patients will be randomly placed in two main groups (StrataXRT) or control group according to randomized numbers obtaining from the website : www.random.org.</study_design>
      <phase>3</phase>
      <hc_freetext>Radiation Induced Dermatitis in Breast Cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: One group of patients from the first day will use the StrataXRT gel twice daily and 5 consecutive days per week for 5-5.5 weeks on radiotherapy area, which has already been identified by the treatment planning system. Patients should wash the radiation site twice daily with water and soap, and then used StrataXRT gel on chest wall with 1-2 mm thickness, and before radiation therapy, to prevent further burns, rinse the area with water and soap. The time interval between using Strata XRT gel twice per day is six hours. this group are examined weekly and in case of second grade dermatitis, they are treated in both groups of patients. In these cases, dermatitis will be evaluated using the grading scale of acute complications according to the following table. This drug contains compounds: polidimetilsilossani,silossani,alchilmetil siliconi, and the compani is manufacturing stratpharma switzerland. Intervention 2: Control group: This group is considered as a control and it is also recommended that they daily wash the radiotherapy area, such as the intervention group and examined weekly and in case of second grade dermatitis, they are treated in the groups of patients. In these cases, dermatitis will be evaluated using the grading scale of acute complications according to the following  special table.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No More Information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Eskandari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 216, Alawi student dormitory., 2Alley.، Mollasadra St.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193613565</zip>
        <telephone>+98 71 4352 3347</telephone>
        <email>Z.e01365@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Omidvari Shapoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hospital Namazi., Zand Street.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71937-11351</zip>
        <telephone>+98 71 3647 4320</telephone>
        <email>Omidvari@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients with newly diagnosed breast cancer undergoing radical mastectomy and candidate for radiation therapy.
Signing the informed consent form.
No contraindication for radiotherapy.
Three weeks after chemotherapy.
Not receiving simultaneously chemotherapy and Herceptin.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>85 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>All patients with history of radiation therapy of breast.
A history of systemic or cutaneous diseases such as diabetes mellitus or collagen vascular disease, and concomitant use of wound healing drugs such as systemic steroids.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: One group of patients from the first day will use the StrataXRT gel twice daily and 5 consecutive days per week for 5-5.5 weeks on radiotherapy area, which has already been identified by the treatment planning system. Patients should wash the radiation site twice daily with water and soap, and then used StrataXRT gel on chest wall with 1-2 mm thickness, and before radiation therapy, to prevent further burns, rinse the area with water and soap. The time interval between using Strata XRT gel twice per day is six hours. this group are examined weekly and in case of second grade dermatitis, they are treated in both groups of patients. In these cases, dermatitis will be evaluated using the grading scale of acute complications according to the following table. This drug contains compounds: polidimetilsilossani,silossani,alchilmetil siliconi, and the compani is manufacturing stratpharma switzerland.</i_keyword>
      <i_keyword>Control group: This group is considered as a control and it is also recommended that they daily wash the radiotherapy area, such as the intervention group and examined weekly and in case of second grade dermatitis, they are treated in the groups of patients. In these cases, dermatitis will be evaluated using the grading scale of acute complications according to the following  special table.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Low Grade Skin Inflammatory Changes. Timepoint: Weekly. Method of measurement: Direct Observation and Transparent Sheet.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Efficacy of StrataXRT gel. Timepoint: Weekly. Method of measurement: Examining the patient's medical records.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-09-30</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>No.216, Alavi Dormitory., 2 Alley., Mollasadra Street. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
